BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome

During transformation, myelodysplastic syndromes (MDS) are characterized by reducing apoptosis of bone marrow (BM) precursors. Mouse models of high risk (HR)-MDS and acute myelogenous leukemia (AML) post-MDS using mutant NRAS and overexpression of human BCL-2, known to be poor prognostic indicators...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorombei, Petra, Guidez, Fabien, Ganesan, Saravanan, Chiquet, Mathieu, Pellagatti, Andrea, Goursaud, Laure, Tekin, Nilgun, Beurlet, Stephanie, Patel, Satyananda, Guerenne, Laura, Le Pogam, Carole, Setterblad, Niclas, de la Grange, Pierre, LeBoeuf, Christophe, Janin, Anne, Noguera, Maria-Elena, Sarda-Mantel, Laure, Merlet, Pascale, Boultwood, Jacqueline, Konopleva, Marina, Andreeff, Michael, West, Robert, Pla, Marika, Adès, Lionel, Fenaux, Pierre, Krief, Patricia, Chomienne, Christine, Omidvar, Nader, Padua, Rose Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508829/
https://www.ncbi.nlm.nih.gov/pubmed/34638998
http://dx.doi.org/10.3390/ijms221910658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508829/
https://www.ncbi.nlm.nih.gov/pubmed/34638998
http://dx.doi.org/10.3390/ijms221910658

Ejemplares similares